# Dita Maixnerová

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dita-maixnerova/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,033 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 28 |
| i10-index | 45 |
| OpenAlex ID | https://openalex.org/A5052083420 |
| ORCID iD | 0000-0002-6733-2857 |
| Works | 81 |

## Researcher papers

Showing 12 of 14.

- [Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens](https://scholariq.org/papers/discovery-of-new-risk-loci-for-iga-nephropathy-implicates-genes-involved-in/)
- [Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis](https://scholariq.org/papers/geographic-differences-in-genetic-susceptibility-to-iga-nephropathy-gwas/)
- [The MEST score provides earlier risk prediction in lgA nephropathy](https://scholariq.org/papers/the-mest-score-provides-earlier-risk-prediction-in-lga-nephropathy/)
- [Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga/)
- [Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial](https://scholariq.org/papers/sparsentan-in-patients-with-iga-nephropathy-a-prespecified-interim-analysis-from/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy](https://scholariq.org/papers/genome-wide-association-analyses-define-pathogenic-signaling-pathways-and/)
- [Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update](https://scholariq.org/papers/is-there-long-term-value-of-pathology-scoring-in-immunoglobulin-a-nephropathy-a/)
- [Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy](https://scholariq.org/papers/development-and-testing-of-an-artificial-intelligence-tool-for-predicting-end/)
- [Markers for the progression of IgA nephropathy](https://scholariq.org/papers/markers-for-the-progression-of-iga-nephropathy/)
- [New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies](https://scholariq.org/papers/new-treatment-strategies-for-iga-nephropathy-targeting-plasma-cells-as-the-main/)
- [Emerging Modes of Treatment of IgA Nephropathy](https://scholariq.org/papers/emerging-modes-of-treatment-of-iga-nephropathy/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Platelet Disorders and Treatments](https://scholariq.org/topics/platelet-disorders-and-treatments/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.